1Cani, PD & Delzenne, NM (2009) The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 15, 1546–1558.
2Hotamisligil, GS (2006) Inflammation and metabolic disorders. Nature 444, 860–867.
3Cai, D, Yuan, M, Frantz, DF, et al. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11, 183–190.
4Hotamisligil, GS, Shargill, NS & Spiegelman, BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87–91.
5Kappelle, PJ, Bijzet, J, Hazenberg, BP, et al. (2011) Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome. Arch Med Res 42, 219–225.
6Ding, S, Chi, MM, Scull, BP, et al. (2010) High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 5, e12191.
7Cani, PD, Bibiloni, R, Knauf, C, et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470–1481.
8Metz, M, Grimbaldeston, MA, Nakae, S, et al. (2007) Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev 217, 304–328.
9Bischoff, SC (2009) Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol 31, 185–205.
10Kovanen, PT (2007) Mast cells: multipotent local effector cells in atherothrombosis. Immunol Rev 217, 105–122.
11Liu, J, Divoux, A, Sun, J, et al. (2009) Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 15, 940–945.
12Galli, SJ, Grimbaldeston, M & Tsai, M (2008) Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 8, 478–486.
13Tlaskalova-Hogenova, H, Stepankova, R, Kozakova, H, et al. (2011) The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 8, 110–120.
14Turnbaugh, PJ, Ridaura, VK, Faith, JJ, et al. (2009) The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1, 6ra14.
15Collins, MD & Gibson, GR (1999) Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 69, 1052S–1057S.
16Fooks, LJ & Gibson, GR (2002) Probiotics as modulators of the gut flora. Br J Nutr 88, Suppl. 1, S39–S49.
17FAO/WHO (2002) Guides for the Evaluation of Probiotics in Food. London/Ontario: Food and Agriculture Organization of the United Nations and World Health Organization.
18Miettinen, M, Veckman, V, Latvala, S, et al. (2008) Live Lactobacillus rhamnosus and Streptococcus pyogenes differentially regulate Toll-like receptor (TLR) gene expression in human primary macrophages. J Leukoc Biol 84, 1092–1100.
19Parvez, S, Malik, KA, Ah Kang, S, et al. (2006) Probiotics and their fermented food products are beneficial for health. J Appl Microbiol 100, 1171–1185.
20Kekkonen, RA, Kajasto, E, Miettinen, M, et al. (2008) Probiotic Leuconostoc mesenteroides ssp. cremoris and Streptococcus thermophilus induce IL-12 and IFN-gamma production. World J Gastroenterol 14, 1192–1203.
21Kekkonen, RA, Lummela, N, Karjalainen, H, et al. (2008) Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults. World J Gastroenterol 14, 2029–2036.
22Saini, R, Saini, S & Sharma, S (2010) Potential of probiotics in controlling cardiovascular diseases. J Cardiovasc Dis Res 1, 213–214.
23Amar, J, Chabo, C, Waget, A, et al. (2011) Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 3, 559–572.
24Lee do, K, Park, SY, Jang, S, et al. (2011) The combination of mixed lactic acid bacteria and dietary fiber lowers serum cholesterol levels and fecal harmful enzyme activities in rats. Arch Pharm Res 34, 23–29.
25Zadelaar, S, Kleemann, R, Verschuren, L, et al. (2007) Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27, 1706–1721.
26Kooistra, T, Verschuren, L, de Vries-van der Weij, J, et al. (2006) Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol 26, 2322–2330.
27Oksaharju, A, Lappalainen, J, Tuomainen, AM, et al. (2009) Pro-atherogenic lung and oral pathogens induce an inflammatory response in human and mouse mast cells. J Cell Mol Med 13, 103–113.
28Fujiyama, Y, Hokari, R, Miura, S, et al. (2007) Butter feeding enhances TNF-alpha production from macrophages and lymphocyte adherence in murine small intestinal microvessels. J Gastroenterol Hepatol 22, 1838–1845.
29Ji, Y, Sakata, Y & Tso, P (2011) Nutrient-induced inflammation in the intestine. Curr Opin Clin Nutr Metab Care 14, 315–321.
30De Winter, BY, van den Wijngaard, RM & de Jonge, WJ (2012) Intestinal mast cells in gut inflammation and motility disturbances. Biochim Biophys Acta 1822, 66–73.
31Sawada, J, Morita, H, Tanaka, A, et al. (2007) Ingestion of heat-treated Lactobacillus rhamnosus GG prevents development of atopic dermatitis in NC/Nga mice. Clin Exp Allergy 37, 296–303.
32Tobita, K, Yanaka, H & Otani, H (2010) Anti-allergic effects of Lactobacillus crispatus KT-11 strain on ovalbumin-sensitized BALB/c mice. Anim Sci J 81, 699–705.
33Huang, J, Zhong, Y, Cai, W, et al. (2010) The effects of probiotics supplementation timing on an ovalbumin-sensitized rat model. FEMS Immunol Med Microbiol 60, 132–141.
34Won, TJ, Kim, B, Lim, YT, et al. (2011) Oral administration of Lactobacillus strains from Kimchi inhibits atopic dermatitis in NC/Nga mice. J Appl Microbiol 110, 1195–1202.
35Senol, A, Isler, M, Karahan, AG, et al. (2011) Effect of probiotics on aspirin-induced gastric mucosal lesions. Turk J Gastroenterol 22, 18–26.
36Okon, K & Stachura, J (2007) Increased mast cell density in renal interstitium is correlated with relative interstitial volume, serum creatinine and urea especially in diabetic nephropathy but also in primary glomerulonephritis. Pol J Pathol 58, 193–197.
37Atkinson, JB, Harlan, CW, Harlan, GC, et al. (1994) The association of mast cells and atherosclerosis: a morphologic study of early atherosclerotic lesions in young people. Hum Pathol 25, 154–159.
38Barbara, G, Stanghellini, V, De Giorgio, R, et al. (2004) Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126, 693–702.
39Nishida, Y, Murase, K, Isomoto, H, et al. (2002) Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease. Hepatogastroenterology 49, 678–682.
40Finamore, A, Roselli, M, Britti, MS, et al. (2012) Lactobacillus rhamnosus GG and Bifidobacterium animalis MB5 induce intestinal but not systemic antigen-specific hyporesponsiveness in ovalbumin-immunized rats. J Nutr 142, 375–385.
41Oksaharju, A, Kankainen, M, Kekkonen, RA, et al. (2011) Probiotic Lactobacillus rhamnosus downregulates FCER1 and HRH4 expression in human mast cells. World J Gastroenterol 17, 750–759.
42Calder, PC, Ahluwalia, N, Brouns, F, et al. (2011) Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr 106, S5–S78.
43Kamada, N, Inoue, N, Hisamatsu, T, et al. (2005) Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. Inflamm Bowel Dis 11, 455–463.
44Angulo, S, Llopis, M, Antolin, M, et al. (2006) Lactobacillus casei prevents the upregulation of ICAM-1 expression and leukocyte recruitment in experimental colitis. Am J Physiol Gastrointest Liver Physiol 291, G1155–G1162.
45Heikkilä, HM, Trosien, J, Metso, J, et al. (2010) Mast cells promote atherosclerosis by inducing both an atherogenic lipid profile and vascular inflammation. J Cell Biochem 109, 615–623.
46Yamashita, M (2008) PPARalpha/gamma-independent effects of PPARalpha/gamma ligands on cysteinyl leukotriene production in mast cells. PPAR Res 2008, 293538.
47Haro, C, Zelaya, H, Lazarte, S, et al. (2009) Lactobacillus casei: influence on the innate immune response and haemostatic alterations in a liver-injury model. Can J Microbiol 55, 648–656.
48Davalos, D & Akassoglou, K (2012) Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 34, 43–62.
49Kotronen, A & Yki-Jarvinen, H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28, 27–38.
50Li, Z, Yang, S, Lin, H, et al. (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37, 343–350.
51Angelakis, E, Bastelica, D, Ben Amara, A, et al. (2012) An evaluation of the effects of Lactobacillus ingluviei on body weight, the intestinal microbiome and metabolism in mice. Microb Pathog 52, 61–68.
52Ouchi, N, Kihara, S, Funahashi, T, et al. (2003) Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14, 561–566.
53Flachs, P, Mohamed-Ali, V, Horakova, O, et al. (2006) Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 49, 394–397.
54Takemura, N, Okubo, T & Sonoyama, K (2010) Lactobacillus plantarum strain no. 14 reduces adipocyte size in mice fed high-fat diet. Exp Biol Med (Maywood) 235, 849–856.
55Mencarelli, A, Distrutti, E, Renga, B, et al. (2011) Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One 6, e22978.
56Hatakka, K, Mutanen, M, Holma, R, et al. (2008) Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp. shermanii JS administered in capsules is ineffective in lowering serum lipids. J Am Coll Nutr 27, 441–447.
57Simons, LA, Amansec, SG & Conway, P (2006) Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol. Nutr Metab Cardiovasc Dis 16, 531–535.
58Nguyen, TD, Kang, JH & Lee, MS (2007) Characterization of Lactobacillus plantarum PH04, a potential probiotic bacterium with cholesterol-lowering effects. Int J Food Microbiol 113, 358–361.
59Fukushima, M, Yamada, A, Endo, T, et al. (1999) Effects of a mixture of organisms, Lactobacillus acidophilus or Streptococcus faecalis on delta6-desaturase activity in the livers of rats fed a fat- and cholesterol-enriched diet. Nutrition 15, 373–378.
60Anderson, JW & Gilliland, SE (1999) Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J Am Coll Nutr 18, 43–50.
61Watts, GF & Dimmitt, SB (1999) Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 10, 561–574.
62van Vlijmen, BJ, van den Maagdenberg, AM, Gijbels, MJ, et al. (1994) Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 93, 1403–1410.
63Wielinga, PY, Yakala, GK, Heeringa, P, et al. (2011) Beneficial effects of alternate dietary regimen on liver inflammation, atherosclerosis and renal activation. PLoS One 6, e18432.